Table 5.

Best response in patients with neuroblastoma, by accession number

	Dose level (mg/m² per dose)	Part	Measurable or evaluable disease	ALK status	Best response (cycle maximum response observed)	Total cycles
*Neuroblastoma ALK* positive (n=11)**
Patient 6	130	A1	Evaluable	Arg1275Leu	SD	4
Patient 12	100	A2	Measurable	Phe1245Cys	PD	2
Patient 23	165	A2	Evaluable	Arg1275Gln	PD	3
Patient 24	165	A2	Measurable	Phe1174Leu	PD	1
Patient 40	165	A2	Measurable	Arg1275Gln^†	SD	>25^*
Patient 25	215	A1	Evaluable	Arg1275Gln	PD	2
Patient 51	215	A2	Evaluable	Phe1174Leu	SD	13
Patient 56	365	A1	Measurable	Arg1275Gln^†	CR (3)	8
Patient 76	280	A2	Measurable	Phe1174Leu	PD	1
Patient 77	280	A2	Evaluable	Phe1174Leu	PD	1
Patient 79	280	A2	Evaluable	Tyr1278Ser	PD	3

*Neuroblastoma ALK* status unknown (n=23)**
Patient 1	100	A1	Evaluable	Not known	PD	1
Patient 7	130	A1	Measurable	Not known	PD	3
Patient 19	130	A3	Measurable	Not known	PD	1
Patient 21	130	A3	Measurable	Not known	PD	1
Patient 13	165	A1	Evaluable	Not known	SD	>39^*
Patient 14	165	A1	Measurable	Not known	PD	2
Patient 16	165	A1	Measurable	Not known	PD	1
Patient 26	165	A3	Evaluable	Not known	PD	1
Patient 32	165	A3	Evaluable	Not known	CR (8)	26
Patient 35	165	A3	Measurable	Not known	PD	3
Patient 44	215	A1	Measurable	Not known	SD	>20^*
Patient 53	215	A3	Measurable	Not known	SD	5
Patient 54	215	A3	Evaluable	Not known	PD	1
Patient 55	215	A3	Evaluable	Not known	SD	10
Patient 46	280	A1	Evaluable	Not known	PD	3
Patient 47	280	A1	Measurable	Not known	SD	>19^*
Patient 49	280	A1	Measurable	Not known	PD	1
Patient 50	280	A1	Evaluable	Not known	PD	1
Patient 61	280	A3	Evaluable	Not known	PD	1
Patient 64	365	A1	Evaluable	Not known	PD	1
Patient 65	280	A3	Measurable	Not known	PD	3
Patient 66	280	A3	Evaluable	Not known	PD	1
Patient 58	365	A1	Evaluable	Not known	PD	1

SD=stable disease. CR=complete response. PD=progressive disease.

Patient still on protocol therapy.

^†

Germline.